Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02223832 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Pharmacokinetics, Tolerability, and Safety of ACT-128800 in Japanese and Caucasian Healthy Male and Female Subjects
A Phase 1 study, sponsored by Actelion.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02223832 is a Phase 1 study that has completed, run by Actelion. The registered enrollment target is 20 participants.
The verdict
NCT02223832, a Phase 1 study, has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a study to evaluate the relative pharmacokinetic properties and the tolerability and safety of ACT-128800 in Japanese and Caucasian healthy male and female subjects after single-dose administration.
Interventions
- DRUG ACT-128800
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2009-02 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02223832
The ClinicalTrials.gov registry entry for NCT02223832 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ACT-128800 is the first listed.
NCT02223832 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02223832 about?
NCT02223832 is a clinical study titled "Study to Evaluate the Pharmacokinetics, Tolerability, and Safety of ACT-128800 in Japanese and Caucasian Healthy Male and Female Subjects". This is a study to evaluate the relative pharmacokinetic properties and the tolerability and safety of ACT-128800 in Japanese and Caucasian healthy male and female subjects after single-dose administration.
What is the current status of trial NCT02223832?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2009-02. Estimated completion is 2009-04.
What interventions are being tested in trial NCT02223832?
The interventions under investigation include: ACT-128800 (DRUG).
Who is sponsoring clinical trial NCT02223832?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.